The European Commission grants Orphan Drug Designation for Intravenous CP-4126 for the Treatment of Pancreatic Cancer

03-Nov-2009 - Clavis Pharma ASA announced that the European Commission has granted Orphan Drug Designation (Orphan Medicinal Product) for Intravenous CP-4126 for the treatment of pancreatic cancer. The designation follows the recommendation given by the European Medicines Agency (EMEA) in September this ...

The European Medicines Agency recommends Orphan Drug Designation of Intravenous CP-4126 for the Treatment of Pancreatic Cancer

15-Sep-2009 - Clavis Pharma announced that the European Medicines Agency (EMEA) has recommended orphan drug designation to Intravenous CP-4126 for the treatment of pancreatic cancer. Clavis Pharma is currently conducting a Phase II study with Intravenous CP-4126 in patients with pancreatic cancer. "We are ...

Clavis Pharma receives USD 1.1 million Grant to Accelerate the Phase II Programme of Intravenous CP-4126 in Pancreatic Cancer

28-Aug-2009 - Clavis Pharma ASA announced that it has received a government grant of up to USD 1.1 mill (NOK 6.9 mill) to accelerate the Phase II clinical programme with Intravenous CP-4126 in patients with newly diagnosed, advanced pancreatic cancer. The grant award was made by Innovation Norway. CP-4126 is ...

Clavis Pharma announces successful Investigational New Drug application (IND) review for Intravenous CP-4126

06-Jul-2009 - Clavis Pharma ASA announces that it has received clearance by the United States Food and Drug Administration (FDA) to include patients in the USA in its phase II clinical programme for Intravenous CP-4126. Intravenous CP-4126 is in development as a new, first-line treatment for pancreatic cancer ...

Clavis Pharma raises USD 20 million in a private placement to fund further development of its anticancer drug pipeline

29-Jun-2009 - Clavis Pharma ASA announced that the Company has raised NOK 129 million (equivalent to USD 20 million) in gross proceeds through a private placement of 10,750,000 new shares, each with a par value of NOK 1.00 at a price of NOK 12.00 per share. The Private Placement took place through a ...

Clavis Pharma: Phase II trial demonstrates Elacytarabine may increase survival threefold in patients with late-stage leukaemia

18-Jun-2009 - Clavis Pharma ASA announced positive final results from a Phase II trial of its novel investigational cancer drug, elacytarabine (CP-4055), in patients with late-stage acute myeloid leukaemia (AML). In the trial, elacytarabine showed statistically significant superior efficacy compared to ...

Clavis Pharma Announces Positive Elacytarabine Phase II Results

Independent data monitoring committee confirms initial results

19-Mar-2009 - Clavis Pharma ASA announced positive results from a second interim analysis of the elacytarabine (CP-4055). Phase II study in patients with late stage acute myeloid leukaemia (AML). An interim analysis of data from 40 patients has been assessed by an independent data monitoring committee. The ...

Clavis Pharma Receives US Orphan Drug Designation for ELACYT(TM)

26-Jun-2008 - Clavis Pharma announced that the US Food & Drug Administration (FDA) has granted orphan drug designation to ELACYT(TM) for the treatment of Acute Myeloid Leukaemia (AML). Within haematology, Clavis Pharma is currently conducting a Phase II study with ELACYT in patients undergoing second salvage ...

Clavis Pharma successfully completes clinical phase I study in haematology

13-Feb-2008 - Clavis Pharma announced that an important milestone has been reached in its haematology program with ELACYT(TM). The phase I part of the ongoing clinical phase I/II study within haematological cancers has been successfully completed. The maximal tolerated dose (MTD) has been determined and ...

Clavis Pharma Completes Executive Management Team

17-Oct-2007 - Clavis Pharma ASA announced the appointment of Jan Alfheim as Chief Business Officer. Mr. Alfheim has more than 20 years of international experience relating to product and corporate development within the pharmaceutical, biotech and chemical industries. Prior to joining Clavis, Mr. Alfheim was ...